Polycystic Ovary Syndrome (PCOS): New Diagnostic Criteria

For decades, diagnosing Polycystic Ovary Syndrome (PCOS) has been a complex, often invasive process involving internal ultrasounds and ambiguous symptom tracking. A major update to international guidelines has fundamentally changed this approach. The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS now recommends the use of Anti-MĂĽllerian Hormone (AMH) levels as a primary diagnostic tool, potentially replacing the need for uncomfortable ultrasounds for many women.

The Shift to Anti-MĂĽllerian Hormone (AMH) Testing

The most significant change in the new guidelines is the inclusion of AMH levels as a valid marker for polycystic ovarian morphology (PCOM). Previously, doctors had to visualize the ovaries using ultrasound technology to count the number of follicles. If a patient had 20 or more follicles per ovary, it met the criteria for PCOM.

Now, a simple blood test can often provide the same answer.

Anti-MĂĽllerian Hormone is a protein made by the cells lining the ovarian follicles. There is a direct correlation between the amount of AMH in the blood and the number of antral follicles in the ovaries. Women with PCOS typically have a higher number of developing follicles, leading to significantly elevated AMH levels compared to women without the condition.

This shift was driven by the Centre for Research Excellence in PCOS at Monash University, which collaborated with over 3,000 health professionals and patients to update the standards. The goal is to reduce barriers to diagnosis and minimize unnecessary invasive procedures.

Why This Change Matters

The move away from mandatory ultrasounds addresses several critical issues in women’s healthcare:

  • Reduced Invasiveness: The most accurate ultrasounds for PCOS are transvaginal. This procedure can be invasive, uncomfortable, and culturally or personally unacceptable for some patients.
  • Accessibility: High-quality ultrasound equipment and specialized sonographers are not available in all regions. Blood tests are widely accessible through standard labs like Quest Diagnostics or LabCorp.
  • Cost: In many healthcare systems, a blood panel is significantly cheaper than an imaging session.

The Updated Rotterdam Criteria

While AMH offers a new way to test, the foundational “Rotterdam Criteria” remains the standard framework for diagnosis. To be diagnosed with PCOS, an adult woman must present two out of the following three features:

  1. Ovulatory Dysfunction: This usually presents as irregular periods or no periods at all. Cycles shorter than 21 days or longer than 35 days are common red flags.
  2. Hyperandrogenism: This refers to high levels of “male” hormones. It can be identified physically (excess facial or body hair, severe acne, female pattern hair loss) or biochemically (blood tests showing elevated testosterone or free androgen index).
  3. Polycystic Ovarian Morphology (PCOM): This is where the new change applies. This third criterion can now be met via elevated AMH levels in the blood or the traditional ultrasound method.

If a patient already has irregular periods and clinical signs of high androgens (like hirsutism), neither an ultrasound nor an AMH test is actually required for diagnosis. The diagnosis is already confirmed by the first two points. The AMH test becomes vital when the patient only has one of the first two symptoms.

Critical Exceptions: Adolescents and Menopause

The new guidelines are very specific about who should receive AMH testing. It is not recommended for adolescents (defined usually as up to 8 years post-menarche).

During puberty, AMH levels naturally fluctuate and are often higher than in adults. Using adult AMH thresholds to diagnose a teenager could lead to a high rate of false positives. For adolescents, the diagnosis should rely primarily on:

  • Biochemical evidence of hyperandrogenism (blood tests).
  • Persistent irregular periods.

Ultrasounds are also less effective for teens due to the preference for abdominal (rather than transvaginal) imaging, which provides lower resolution. Consequently, doctors are advised to be more conservative when diagnosing teens, often labeling them “at risk” rather than confirming PCOS immediately.

Similarly, AMH is not a reliable diagnostic tool for women approaching menopause. As the ovarian reserve naturally diminishes with age, AMH levels drop, potentially masking the presence of PCOS.

The Role of Ultrasound Remains

While AMH is a breakthrough, ultrasound is not obsolete. The guidelines suggest that ultrasound should still be used if:

  • AMH testing is unavailable or cost-prohibitive.
  • The doctor needs to rule out other pathology, such as ovarian cysts or tumors.
  • The patient is an adolescent and requires imaging for reasons other than follicle counting.

However, for the standard adult patient suspected of having PCOS, the days of mandatory transvaginal ultrasounds are fading.

Moving Toward Personalized Management

The update extends beyond diagnosis into management. The guidelines emphasize that PCOS is not just a fertility issue but a metabolic one. Once diagnosed—whether via AMH or ultrasound—the focus shifts to long-term health.

Key management updates include:

  • Cardiovascular Health: Regular screening for lipid profiles and blood pressure is recommended for all PCOS patients, regardless of weight.
  • Glucose Tolerance: The guidelines recommend the oral glucose tolerance test (OGTT) as the most accurate way to screen for insulin resistance and Type 2 diabetes, which affects a large percentage of women with PCOS.
  • Lifestyle Interventions: Before medication, specific lifestyle changes regarding diet and exercise remain the first line of defense.
  • Medical Support: Metformin and inositol are highlighted as effective treatments for metabolic issues, while combined oral contraceptive pills remain the primary treatment for managing irregular cycles and androgen symptoms.

By simplifying the diagnosis with AMH testing, patients can move faster from the “discovery” phase to the “management” phase, potentially preventing long-term complications like diabetes and endometrial cancer.

Frequently Asked Questions

What is a “high” AMH level for PCOS diagnosis? While laboratories vary, an AMH level generally above 3.0 to 4.0 ng/mL is often considered indicative of polycystic ovaries in the context of PCOS. However, your doctor must interpret this based on your specific age and the specific assay (test method) used by the lab.

Can I diagnose PCOS with at-home hormone test kits? Many companies like Everlywell or LetsGetChecked offer at-home fertility tests that measure AMH. While these provide data, a diagnosis requires a doctor to evaluate that data alongside your menstrual history and physical symptoms. You cannot self-diagnose PCOS based solely on an at-home test result.

Does high AMH mean I am very fertile? High AMH indicates a high number of eggs (ovarian reserve), which is generally good for fertility. However, in PCOS, these eggs often do not mature or release properly (ovulate). Therefore, you can have high AMH but still face difficulty conceiving due to lack of ovulation.

Is the AMH test covered by insurance? Coverage varies. Some insurance plans cover AMH testing for diagnostic purposes (code Z01.419 or similar), while others categorize it strictly under “infertility testing,” which may not be covered. It is important to verify with your provider if the test is being ordered for “PCOS diagnosis” rather than “fertility assessment” to improve the chances of coverage.